Amy Moskop

1.3k total citations
22 papers, 65 citations indexed

About

Amy Moskop is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Amy Moskop has authored 22 papers receiving a total of 65 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 6 papers in Public Health, Environmental and Occupational Health and 4 papers in Genetics. Recurrent topics in Amy Moskop's work include CAR-T cell therapy research (18 papers), Acute Lymphoblastic Leukemia research (6 papers) and Virus-based gene therapy research (4 papers). Amy Moskop is often cited by papers focused on CAR-T cell therapy research (18 papers), Acute Lymphoblastic Leukemia research (6 papers) and Virus-based gene therapy research (4 papers). Amy Moskop collaborates with scholars based in United States, India and Switzerland. Amy Moskop's co-authors include Lauren Pommert, Rachel Phelan, Michael A. Pulsipher, Marcelo C. Pasquini, Julie‐An Talano, Matthew J. Frigault, André Baruchel, John F. DiPersio, Colleen Annesley and Lohith Gowda and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Amy Moskop

16 papers receiving 65 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Moskop United States 6 58 17 13 11 11 22 65
Shuixiu Peng China 2 46 0.8× 15 0.9× 10 0.8× 20 1.8× 7 0.6× 3 51
Danielle Pinner United Kingdom 2 52 0.9× 51 3.0× 8 0.6× 37 3.4× 10 0.9× 3 84
Tiarlan Sirait France 4 30 0.5× 10 0.6× 3 0.2× 6 0.5× 6 0.5× 6 43
Toni Foley United States 3 40 0.7× 7 0.4× 13 1.0× 3 0.3× 5 0.5× 8 50
Khushnuma Mullanfiroze India 3 31 0.5× 11 0.6× 3 0.2× 11 1.0× 6 0.5× 10 40
Maria Almena-Carrasco France 3 36 0.6× 17 1.0× 3 0.2× 9 0.8× 5 0.5× 3 36
Zhuqing Xiong China 2 26 0.4× 18 1.1× 4 0.3× 8 0.7× 6 0.5× 2 51
Shoba A. Navai United States 4 28 0.5× 7 0.4× 16 1.2× 5 0.5× 6 0.5× 9 46
Ouiam Bakkacha United States 3 51 0.9× 18 1.1× 2 0.2× 11 1.0× 7 0.6× 5 57
Jufen Chu United States 4 43 0.7× 9 0.5× 2 0.2× 8 0.7× 5 0.5× 5 55

Countries citing papers authored by Amy Moskop

Since Specialization
Citations

This map shows the geographic impact of Amy Moskop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Moskop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Moskop more than expected).

Fields of papers citing papers by Amy Moskop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Moskop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Moskop. The network helps show where Amy Moskop may publish in the future.

Co-authorship network of co-authors of Amy Moskop

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Moskop. A scholar is included among the top collaborators of Amy Moskop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Moskop. Amy Moskop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
John, Samuel, Kevin J. Curran, Amy K. Keating, et al.. (2025). Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Advances. 9(20). 5249–5262.
2.
3.
Capitini, Christian M., Amy Moskop, Anant Vatsayan, et al.. (2024). Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood Advances. 8(15). 4164–4168. 2 indexed citations
4.
Talleur, Aimee C., Vanessa A. Fabrizio, Richard Aplenc, et al.. (2024). INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplantation and Cellular Therapy. 30(6). 565–579. 1 indexed citations
5.
Landsburg, Daniel J., Richard T. Maziarz, Amy Moskop, et al.. (2024). Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 144(Supplement 1). 4398–4398. 1 indexed citations
6.
7.
8.
Landsburg, Daniel J., Amy Moskop, S.R. Foley, et al.. (2024). Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Transplantation and Cellular Therapy. 30(2). S187–S188.
9.
Strouse, Christopher, Umar Farooq, Roni Shouval, et al.. (2024). Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 144(Supplement 1). 609–609.
10.
McNerney, Kevin O., Amy Moskop, Lena E. Winestone, et al.. (2023). Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 30(1). 75.e1–75.e11. 4 indexed citations
11.
12.
Schultz, Liora M., Elad Jacoby, Adam J. Lamble, et al.. (2023). Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium. Transplantation and Cellular Therapy. 29(10). 592–593. 2 indexed citations
13.
Landsburg, Daniel J., Amy Moskop, S.R. Foley, et al.. (2023). Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Blood. 142(Supplement 1). 3496–3496. 2 indexed citations
14.
Lamble, Adam J., Amy Moskop, Michael A. Pulsipher, et al.. (2023). INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 29(11). 674–684. 8 indexed citations
15.
Furqan, Fateeha, Julie‐An Talano, Amy Moskop, et al.. (2023). Clinical Characteristics and Patient Outcomes with HLH-like Toxicities after CD19 Based CAR T-Cell Therapy. Transplantation and Cellular Therapy. 29(2). S131–S132.
16.
McNerney, Kevin O., Rebecca M. Richards, Paibel Aguayo‐Hiraldo, et al.. (2023). SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. Journal for ImmunoTherapy of Cancer. 11(1). e005957–e005957. 6 indexed citations
17.
Mirza, Abu‐Sayeef, Chitra Hosing, Francine M. Foss, et al.. (2022). Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR). Blood. 140(Supplement 1). 4633–4635. 7 indexed citations
18.
19.
Moskop, Amy, et al.. (2020). Chimeric antigen receptor T‐cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia. Pediatric Blood & Cancer. 68(1). e28739–e28739. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shuixiu Peng Breakdown of academic impact, for papers by Danielle Pinner Breakdown of academic impact, for papers by Tiarlan Sirait Breakdown of academic impact, for papers by Toni Foley Breakdown of academic impact, for papers by Khushnuma Mullanfiroze Breakdown of academic impact, for papers by Maria Almena-Carrasco Breakdown of academic impact, for papers by Zhuqing Xiong Breakdown of academic impact, for papers by Shoba A. Navai Breakdown of academic impact, for papers by Ouiam Bakkacha Breakdown of academic impact, for papers by Jufen Chu
Rankless by CCL
2026